LLS backs 5 new can­cer drug projects with up to $50M; Trodelvy con­tin­ues to im­press with more TNBC da­ta

The Leukemia and Lym­phoma So­ci­ety has tapped 5 new ear­ly-stage projects to back with up to $10 mil­lion each in fresh in­vest­ments. The 5 biotechs are:

— Cari­bou, head­ed by Rachel Hau­r­witz and co-found­ed by Jen­nifer Doud­na, is work­ing on next-gen, off-the-shelf CAR-Ts to re­place the pa­tient-de­rived cells now in use.

— The LLS sup­port­ed Nex­Im­mune’s IPO, help­ing fund its work on nanopar­ti­cles that can gin up an im­mune re­sponse di­rect­ed at can­cer cells. The biotech has 2 projects now in Phase I tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA